TempraMed Technologies announced that Maccabi Healthcare Services, Israel's second-largest HMO serving over 2.6 million members, has extended its agreement with TempraMed for another year under the same terms. This extension validates TempraMed's patented temperature-protection technology for injectable medications like insulin and peptides within a large healthcare system. The continued partnership highlights the relevance of TempraMed's products in supporting chronic condition management and expanding its global healthcare collaborations. Additionally, TempraMed reported the resignation of board member Nancy Goertzen effective August 19, 2026.
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
Grey Matters Health announced plans to raise up to C$800,000 through a non-brokered private placement combining equity units and convertible debentures. The funds will support its Alzheimer's disease program and the launch of brain-specific neuroimag...
Xiaomi Corporation's Q2 2026 results met expectations, showing improved year-on-year revenue contraction and quarter-on-quarter earnings growth. The company's strategy to move upmarket supports margin stability in its smartphone business despite memo...
Ideal Power Inc is gaining momentum with its B-TRAN semiconductor technology, driven by increasing demand for solid-state circuit protection in AI data centers, energy infrastructure, and automotive sectors. The company’s sales funnel has grown to ov...
Citi raised earnings forecasts for GSK following its Accelerate Growth event and Q2 results, supported by a £1.9 billion cost-saving plan reinvested into R&D. This funds 20 phase III trials in 2026, expected to boost earnings per share by 1-4% from 2...
